CN1820618A - Health preserving liver protection tea and its preparing method - Google Patents
Health preserving liver protection tea and its preparing method Download PDFInfo
- Publication number
- CN1820618A CN1820618A CN 200610066319 CN200610066319A CN1820618A CN 1820618 A CN1820618 A CN 1820618A CN 200610066319 CN200610066319 CN 200610066319 CN 200610066319 A CN200610066319 A CN 200610066319A CN 1820618 A CN1820618 A CN 1820618A
- Authority
- CN
- China
- Prior art keywords
- group
- root
- weight portion
- weight
- health preserving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to health preserving and liver protecting tea and its preparation process. The health preserving and liver protecting tea is prepared with nine kinds of Chinese medicinal materials, including gynostemma pentaphylla, haw, wolfberry fruit, red sage, fleeceflower root, etc in certain weight proportion, and through water decoction or alcohol extraction, mixing, drying, frying, bagging, Co-60 irradiation and other steps. The medicinal tea contains rich nutrients, and animal experiment and practical application proves its functions of preventing and treating chemical liver damage, raising body's immunity and helping treatment of fatty liver and no toxic side effect.
Description
Technical field
The present invention relates to a kind of health preserving liver protection tea and preparation method thereof, a kind of specifically is the Tea containing traditional Chinese medicine and preparation method thereof of raw material with the Chinese herbal medicine, belongs to Chinese medicine health technical field.
Background technology
Liver is the substantive digestive organs of human body maximum, various nutriments are transformed into protein, lipid and the glycogen of biologically active, thereby have ensured the functional activity of internal organs such as human body each organ, the especially heart, brain, kidney, have healthy liver, will have healthy health.
Owing to growth in the living standard, dietary structure changes and the prevention and health care measure relatively lags behind in recent years.China has long spirits culture history, and under this big environmental background, makes warmhearted and hospitable Chinese mostly have the custom of drinking, push away the cup change between small cup, have when drinking beyond one's capacity unavoidably, and drink each time, what damage was maximum has been exactly liver.The drunk deeply hepatitis that once just equals one time of the people of saying on the books, and the hepatic injury that is caused by wine now is to increase year by year, and because other relevant chronic diseases that hepatic injury caused and cause the autoimmunity ability low just more.
The variation of social environment on the other hand, bring the new synthetic medicament and the increase of chemicals, patient's long-term prescription is taken medicine, in case the medicine toxic side effect, the liver that this toxic and side effect can only rely on human body is alleviated, if the patient originally has a delicate constitution, liver function is unsound, thus, vicious circle especially, this is just the same with alcoholism, is the another reason that produces chemical damage.In addition, because fast development, the increased population of industry, the demand of diet product such as vegetable and fruit increases year by year, and most of grower uses fertilizer and pesticide in the process of plantation, also is a big principal element of liver injury because problems such as residues of pesticides cause toxicant accumulating in human body.
Because the quickening day by day of rhythm of life, operating pressure is excessive, and the irregular feasible most of crowd that lives is in sub-health state, and people's hypoimmunity is the basic of many sick morbidities.
The medicine Chinese and Western medicine of treatment chemical damage accounts for the overwhelming majority, and the equal toxic side effect of Western medicine also brings new difficulty for treatment of diseases.And the Chinese medicine major part that is used for chemical damage at present is cold in nature, reaches the purpose for the treatment of hepatic injury by falling irascibility, and this medicine can not be applicable to the hepatic injury of diversification, and result of treatment is undesirable, can not play the effect of prevention chemical damage.
Therefore, people can improve body immunity again simultaneously for preventing and treat chemical damage, and the Chinese herb medicine health that has no side effect conditioning has very big demand.
Existing medicine mostly is tablet greatly, capsule is in the majority, people are busy with one's work and can not accomplish regularly to take also and can affect the treatment, another characteristics of the present invention are Chinese herb medicine of the present invention to be made traditional medicinal herb tea formulation drink, everybody needs to have tea every day, taking convenience absorbs rapidly, is applicable to fast pace, high efficiency work and study and Chinese habits and customs.
At present domestic in the middle of the development of health preserving liver protection tea still blank, the neither one curative effect is stable, instant effect, the good taking convenience of mouthfeel, the medicine-food two-purpose tea of being free from side effects again.
Summary of the invention
In sum, people to curative effect stablize, have no side effect, still there is very big demand in the health preserving liver protection medicinal herb tea of taking convenience.The inventor is through research repeatedly, and by clinical trial and zooperal checking repeatedly, found finally better curative effect and taking convenience are arranged, health preserving liver protection tea that mouthfeel is good, thereby finished the present invention.
The purpose of this invention is to provide a kind of health preserving liver protection tea.
Another object of the present invention provides the preparation method of this health preserving liver protection tea.
Technical scheme of the present invention is that the inventor is based on understanding and the maintenance principle of motherland's traditional medicine to liver protecting, with reference to the modern pharmacological research achievement, through verifying what screening drew repeatedly.The present invention selects gynostemma pentaphylla, hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel and dandelion to make up, and cooperate each raw material weight proportioning of the present invention to make each efficacy of drugs produce synergy, strengthen immunity of organisms and nurse one's health the effect that chemistry is done damage thereby can effectively play.
Wherein select gynostemma pentaphylla to be because it contains gynosaponin, amino acid, trace element and polysaccharide.Bitter, cold in nature, the thoughts of returning home, liver, kidney channel.It has hypotensive, reducing blood lipid, prevents the cell cancerization, strengthens immunity of organisms and the anti-ageing effect of waiting for a long time.
Hawthorn flavor acid, sweet, warm in nature, return spleen, stomach, Liver Channel, it mainly contains flavone compound Quercetin, quercitrin, hyperin, arrow east chrysanthemum element, cachou extract etc., and organic acid crataegolic acid, citric acid, malic acid, citric acid, chlorogenic acid, oleanolic acid, ursolic acid etc., has promoting digestion and removing indigestion, the effect of promoting blood circulation to remove blood stasis.
The fruit of Chinese wolfberry contains betaine, rutin, β-D-glycoside, zeaxanthine, physalin, also contains multivitamin, amino acid and micro-calcium, phosphorus, iron etc.Its flavor is sweet, and property is flat.Return liver, kidney channel.Effect such as have nourishing kidney and replenishing pneuma, nourish the liver to improve visual acuity.
The red sage root contains ginseng ketone I, II
A, III
B, isotanshinone I, II, Cryptotanshinone, dihydroisotanshinones etc. also contain danshensu, protocatechualdehyde, vitamin E, cupreol, hydroxyl Tanshinone I I
A, saivianic acid A fat, methylene tanshinquinone, danshenxinkun etc.Its bitter, cold nature, thoughts of returning home Liver Channel.Have coronary artery dilator, increase coronary blood flow, improve myocardial function, the expansion peripheral vascular suppresses platelet aggregation, and nervous system is had calm and stable effect.
The fleece-flower root contains anthraquinone derivatives Chrysophanol, archen, Rhein, chrysophanic acid anthrone and lecithin etc., still contains stilbene compound 2,3,5, and the 4-tetrahydroxy is done styrene-2-O-β-D-glucose and reached gallic acid, starch, fat oil, cupreol etc.Its bitter, sweet, puckery, slightly warm in nature is returned liver, kidney channel.Have and tonify the liver and kidney, nourish essence and blood, relax bowel the effect of detoxifying and relieving itching.
Glossy ganoderma contains glossy ganoderma polysaccharide, several amino acids, multiple biological alkali (as r-three methylamino butyric acid etc.), ergosterol, coumarin, organic acid, vitamin etc.The property sweet, lightly seasoned, little hardship, flat.Return the spleen channel, lung channel, the heart channel of Hang-Shaoyin, Liver Channel, kidney channel.The glossy ganoderma pharmacological action has replenishing qi and blood, mends marrow, and mental-tranquilization is relieving cough and asthma.
Root of kudzu vine main component is an isoflavonoid, includes big legumin, daidzin, Puerarin, also contains cupreol, lupenone, allantoin, docosoic acid, arachidic acid and volume starch.Its flavor is sweet, hot, and property is flat.Return spleen, stomach warp.It has relieving muscles to expel heat, and promoting eruption promotes the production of body fluid to quench thirst, and rises the effect of positive antidiarrheal.
Dried orange peel is the pericarp of rutaceae orange.Contain hesperidine, Nobiletin, citrene, a-firpene, B-firpene, B-phellandrene etc.Nature and flavor: warm in nature, bitter, suffering.Function cures mainly: regulating qi-flowing for strengthening spleen is eliminating dampness and eliminating phlegm.Be used for chest gastral cavity turgor, the few vomiting and diarrhoea of food, cough ant phlegm.
Dandelion mainly contains taraxasterol, choline, synanthrin and pectin etc.Its water extract has inhibitory action to staphylococcus aureus, hemolytic streptococcus, and pneumococcus, meningococcus, hemolytic streptococcus etc. are also had certain inhibitory action.Its bitter, sweet, cold in nature.Return liver, stomach warp.Have effects such as clearing heat and detoxicating, eliminating dampness and heat.
Above-mentioned 9 flavor medicines make up, strengthen body immunity, nurse one's health various chemical damage best results, and the consumption of drug component of the present invention is also groped to sum up to draw through the inventor for a long time in a large number, and each amounts of components all has better curative effect and without any side effects in the following weight scope.
For realizing purpose of the present invention, following concrete technical scheme is proposed: a kind of health preserving liver protection tea, it is to be made by the following weight proportion raw material:
Gynostemma pentaphylla 15～25 weight portion hawthorn 9～16 weight portion fruits of Chinese wolfberry 11～16 weight portions
The red sage root 6～10 weight portion fleece-flowers root 6～10 weight portion glossy ganodermas 7～15 weight portions
The root of kudzu vine 5～12 weight portion dried orange peels 3～9 weight portion dandelions 2～8 weight portions
Described a kind of health preserving liver protection tea, the optimum weight proportioning of its each raw material is:
Gynostemma pentaphylla 15～20 weight portion hawthorn 12～16 weight portion fruits of Chinese wolfberry 12～16 weight portions
The red sage root 8～10 weight portion fleece-flowers root 8～10 weight portion glossy ganodermas 10～15 weight portions
The root of kudzu vine 8～10 weight portion dried orange peels 5～9 weight portion dandelions 5～8 weight portions
The preparation method of described a kind of health preserving liver protection tea, it comprises the following steps:
(1) take by weighing gynostemma pentaphylla, hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, dandelion by described weight proportion, standby;
(2) with hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, the dandelion boiling of described weight proportion, extract is concentrated to and records relative density when 60 spend is 1.09～1.2 concentrate;
(3) gynostemma pentaphyllum powder of described weight proportion is broken to the meal of 50 order fineness;
(4) with concentrate when keeping 36 degree temperature and the gynostemma pentaphylla meal mix, fry and mix 75～95 minutes, promptly be prepared into active component of the present invention.
The preparation method of described a kind of health preserving liver protection tea, wherein boiling three times in the step (2) adds 10 times of amounts of water for the first time and soaks after 190 minutes, decocts 180 minutes, add for the second time 6 times of amounts of water decoct 120 minutes, add 2 times of amount decoctions of water 65 minutes for the third time.
The preparation method of described a kind of health preserving liver protection tea, the active component that wherein step (4) is made pack back under 70 ℃～80 ℃ temperature dry 9～12 hours promptly makes medicinal tea.
The preparation method of described a kind of health preserving liver protection tea, the active component that wherein step (4) can also be made pack back 180 minutes, promptly makes medicinal tea with 4 KGY of cobalt-60 irradiation.
The described fleece-flower root should be used RADIX POLYGONI MULTIFLORI PREPARATA, and described dried orange peel is an orange peel.
The preparation method of the described health preserving liver protection tea active component of the invention described above is to adopt water to put forward the method for combination, and it is a preferred method of the present invention.Can also be prepared with the method for alcohol extracting, wherein can adopt alcohols such as ethanol, isopropyl alcohol, propyl alcohol or butanols, but the alcohol extract best results.As follows with concrete grammar:
(1) take by weighing each raw material gynostemma pentaphylla, hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, dandelion by weight proportion of the present invention, standby;
(2) except that gynostemma pentaphylla be that the alcohol immersion of 50%-90% is put into the reflux alcohol reflux and extracted three times after 24 hours, for the first time with 8 times of amount alcohol refluxs 2 hours, measure alcohol refluxs 1.5 hours, measured alcohol refluxs 1 hour with 4 times for the third time with 6 times for the second time with each bulk drug volume ratio;
(3) reclaim extract also by 120 order stainless steel sift net filtrations;
(4) extract after will sieving 45～50 ℃ dry down, obtain dry extract;
(5) gynostemma pentaphylla with dry extract and described weight proportion mixes, and has promptly made active component of the present invention.
With the dry pack of above-mentioned active component, promptly made the medicinal tea finished product.
The interpolation times magnitude relation of above-mentioned ethanol or water and medicine is ethanol or water and the ratio of the weight of medicine.
A kind of health preserving liver protection tea provided by the present invention; raw materials used by described weight part ratio; and the preparation method of Chinese formulated products makes various formulations routinely; as medicinal tea, pill, oral liquid, pill etc.; but these are not limited to protection scope of the present invention, and wherein medicinal tea is a preferred dosage form of the present invention.
Instructions of taking: 6g/ time, three times on the one, boiling water brews to drink and gets final product.
Important feature of the present invention is to contain rich nutrient contents in the medicament, wherein contains multiple saponin, organic acid, Glucosamine and polysaccharide.Only one of gynostemma pentaphylla just contains 80 kinds of saponins.This nutritional labeling all has better action to nursing one's health all kinds of chemical damages and improving immunity of organisms, and has no side effect, and is fit to take for a long time.
Each nutrition content sees Table 1 in the medicinal tea of the present invention:
Table 1
| Title | Content (mg/100g) | Title | Content (mg/100g) | Title | Content (mg/100g) |
| Saponin | 689.3 | Polysaccharide | 965.6 | Organic acid | 196.9 |
| Amino acid | 1063.0 | Alkaloid | 219.5 | Flavonoids | 736.5 |
Also contain various trace elements such as vitamin C, vitamin E, vitamin B6, calcium, phosphorus, iron, zinc and folic acid in the health preserving liver protection tea of the present invention in addition.These vitamins are prothetic groups of body repair cell, can protect liver cell and improve immunity of organisms.Vitamin of the present invention and micronutrient levels see Table 2:
Table 2
| Title | Content (mg/100g) | Title | Content (mg/100g) | Title | Content (mg/100g) |
| Calcium | 1178 | Zinc | 17.81 | Vitamin C | 88 |
| Phosphorus | 1033 | Iron | 68.1 | Vitamin B6 | 0.28 |
Verify that by following zoopery health preserving liver protection tea of the present invention has the effect of conditioning and prevention chemical damage.
(1) animal used as test:
The healthy cleaning level of 18～22g Kunming kind of the Department Of Medicine, Peking University department of the Chinese Academy of Sciences of animal used as test section [credit number: SCXK-(capital) 2002-0001] breeding male mice.
(2) instrument and reagent:
Disscting instrument, filling stomach pin, AE100 electronic balance (96009), 755 type spectrophotometers (2002001), physiological saline, 2M phosphate buffer (pH7.4)
Carbon tetrachloride (CCl
4), chemical reagent two factories in Zhengzhou produce, lot number 980906.
Bio-engineering research institute lot number is built up in MDA kit Nanjing: 20040404
Bio-engineering research institute lot number is built up in glutathione kit Nanjing: 20050615
Triglycerides kit Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd. lot number: 220501
(3) experimental technique:
After setting up the damage mould, each group is carried out the mensuration of MDA, reduced glutathione and triglycerides in the hepatic tissue, relatively curative effect.
(4) modeling success standard:
In model control group and the blank group comparison hepatic tissue MDA, reduced glutathione and/or content of triglyceride significantly raise (P＜0.01) illustrate that model sets up successfully.
(5) effect judgment criteria:
Set up on the successful basis at model, mda content is starkly lower than model control group and difference has conspicuousness (P＜0.05) in the liver, i.e. this index of decidable positive as a result; Reduced glutathione content is significantly higher than model control group, and difference has conspicuousness (P＜0.05), i.e. this index of decidable positive as a result; Triglycerides is starkly lower than model control group and difference has conspicuousness (P＜0.05), i.e. this index of decidable positive as a result; Three are detected any two index positives in the index, and promptly decidable medicinal herb tea of the present invention has the effect of treatment and prevention chemical damage.
Experimental example 1
1, grouping: 60 mouse are divided into 6 groups, are respectively: be grown up 5 times, 10 times, 30 times of dosage (every days 12 gram) of the present invention are basic, normal, high dosage group, blank group, model control group 1 and model control group 2.
2, experimentation: with medicine water preparation of the present invention, per os gives once a day, continuous irrigation stomach 45 days, and the filling body of stomach is long-pending to be 0.2ml/10g mouse weight, blank group and model control group 1,2 equal waters replace medicine of the present invention, irritate body of stomach every day and amass identical with medicine group of the present invention.After finishing, give 50% ethanol 12ml/kgBW with model control group 1 disposable filling stomach, model control group 2 is pressed 0.2ml/10g body weight hypodermic injection 40% carbon tetrachloride olive oil solution, and the blank group gives sterilized water.The fasting overnight of each treated animal was put to death after 16 hours, carried out every index and detected.
3, zoopery result judges:
Table 3 medicinal herb tea of the present invention is to the influence of mda content in the hepatic tissue
| Group | Number of animals (only) | MDA (nmol/mg tissue) | The P value |
| Dosage group high dose group in model control group 1 model control group 2 low dose group | 10 10 10 10 10 | 0.100±0.029 0.120±0.024 0.086±0.018 0.075±0.023* 0.070±0.051* | - - - P＜0.05 P＜0.05 |
| The blank group | 10 | 0.048±0.006* | P＜0.01 |
*: with model control group relatively there were significant differences property
By table 3 as seen, model control group 1,2 and blank group comparison mda content significantly raise (P＜0.01), illustrate that liver injury model sets up successfully.Middle dosage group and high dose group and model control group 1,2 compare, and mda content significantly reduces (P＜0.05), the positive as a result in the hepatic tissue.
Table 4 medicinal herb tea of the present invention is to the influence of content of triglyceride in the hepatic tissue
| Group | Number of animals (only) | Triglycerides (mmol/g tissue) | The P value |
| Dosage group high dose group in model control group 1 model control group 2 low dose group | 10 10 10 10 10 | 0.042±0.012 0.045±0.010 0.034±0.010 0.029±0.028* 0.028±0.012* | - - - P＜0.05 P＜0.05 |
| The blank group | 10 | 0.019±0.004* | P＜0.01 |
*: with model control group relatively there were significant differences property
By table 4 as seen, model control group 1,2 and blank group comparison content of triglyceride significantly raise (P＜0.01), illustrate that liver injury model sets up successfully.Middle dosage group and high dose group and model control group 1,2 compare, and content of triglyceride significantly reduces (P＜0.05), the positive as a result in the hepatic tissue.
Table 5 medicine of the present invention is to the influence of reduced glutathione content in the hepatic tissue
| Group | Number of animals (only) | Glutathione (μ mol/g tissue) | The P value |
| Dosage group high dose group in model control group 1 model control group 2 low dose group | 10 10 10 10 10 | 14.1±2.6 14.3±2.0 16.2±2.0 18.0±1.5* 18.2±1.3* | - - - P＜0.05 P＜0.05 |
| The blank group | 10 | 18.6±3.0* | P＜0.01 |
*: with model control group relatively there were significant differences property
By table 4 as seen, model control group 1,2 and blank group comparison reduced glutathione content significantly reduce (P＜0.01), illustrate that liver injury model sets up successfully.In dosage group and high dose group and model control group 1,2 comparisons, significantly raise (P＜0.05), the positive as a result of reduced glutathione content in the hepatic tissue.
In a word, model control group 1,2 and blank group relatively mda content, reduced glutathione content and content of triglyceride all significantly raise, and illustrate that model sets up successfully.Per os gives the medicine of the present invention 45 days of mouse various dose, compare with model control group 1 (alcoholic hepatic injury model) and model control group 2 (carbon tetrachloride damage model), mda content is starkly lower than model control group 1,2, and difference has conspicuousness (P＜0.05), and this index of decidable is the positive as a result; Reduced glutathione content is significantly higher than model control group 1,2, and difference has conspicuousness (P＜0.05), and this index of decidable is the positive as a result; Triglycerides is starkly lower than model control group 1,2, and difference has conspicuousness (P＜0.05), and this index of decidable is the positive as a result; Three detection indexs are all positive, and decidable medicine of the present invention has the effect of prevention chemical damage.
Experimental example 2
1, grouping: 50 mouse are divided into 5 groups, are respectively: 5 times, 10 times, 30 times of normal control group, medicine human dose of the present invention is basic, normal, high dosage group, model control group.
2, animal modeling: except that the normal control group, all the other each mouse are pressed 0.2ml/10g body weight hypodermic injection 40%CCl
4Olive oil solution, weekly twice, totally 6 weeks.After 6 weeks, disposable filling stomach gives 50% ethanol 12ml/kgBW, irritates body of stomach and amasss to the 0.1ml/10g mouse weighs, and normal control group water replaces ethanol.
3, grouping and administration:
All the other each mouse except that the normal control group are divided into 4 groups at random, be respectively basic, normal, high dosage group and model control group, normal control group and model control group are irritated stomach with sterilized water 5ml/kg, basic, normal, high dosage group is irritated stomach medicine of the present invention with 5ml/kg, 2 totally 6 weeks weekly, the fasting overnight of 6 week each treated animal of back was put to death after 16 hours, carried out every index and detected.
4, zoopery result judges:
Table 6 medicine of the present invention is to the influence of mda content in the hepatic tissue
| Group | Number of animals (only) | MDA (nmol/mg tissue) | The P value |
| Dosage group high dose group in the model control group low dose group | 10 10 10 10 | 0.150±0.027 0.049±0.018 0.047±0.010* 0.046±0.008* | - - P＜0.05 P＜0.05 |
| The normal control group | 10 | 0.046±0.005* | P＜0.01 |
*: with model control group relatively there were significant differences property
By table 3 as seen, model control group and normal control group comparison mda content significantly raise (P＜0.01), illustrate that liver injury model sets up successfully.Middle dosage group and high dose group and model control group compare, and mda content significantly reduces (P＜0.05) in the hepatic tissue, and near normal value, decidable is the positive as a result.
Table 7 medicine of the present invention is to the influence of content of triglyceride in the hepatic tissue
| Group | Number of animals (only) | Triglycerides | The P value |
| (mmol/g tissue) | |||
| Dosage group high dose group in the model control group low dose group | 10 10 10 10 | 0.060±0.012 0.019±0.020 0.018±0.016 0.017±0.011* | - - - P＜0.05 |
| The normal control group | 10 | 0.017±0.009* | P＜0.01 |
*: with model control group relatively there were significant differences property
By table 7 as seen, model control group and blank group comparison content of triglyceride significantly raise (P＜0.01), illustrate that liver injury model sets up successfully.High dose group and model control group relatively, content of triglyceride significantly reduces (P＜0.05) in the hepatic tissue, and near normal value, as a result the positive.
5, presentation of results:
Model control group and blank group comparison mda content and content of triglyceride significantly raise, and illustrate that model sets up successfully.Per os gives 6 weeks of medicine of the present invention of mouse various dose, compares with model control group, and mda content is starkly lower than model control group, and difference has conspicuousness (P＜0.05) this index of decidable positive as a result; Triglycerides is starkly lower than model control group and difference has conspicuousness (P＜0.05), this index of decidable is the positive as a result: three detect in the indexs two all positive, and the MDA of high dose group and the content value of triglyceride are close with normal value, and decidable medicine of the present invention has the effect of treatment chemical damage.
CCl
4Damage is because CCl to hepatotoxicity wind agitation
4Be metabolized to the trichloromethyl free radical through hepatocyte microsome inner cell cytochrome p 450, and in the peroxidating chain reaction of its startup, superoxide anion that the toxigenicity effect is stronger and hydroxyl ion, these free radicals damage liver cell by lipid peroxidation.Peroxidatic reaction of lipid also can be directly or the peroxidating product by aldehyde act on fat-storing cell, or Kupffer Cell discharges cell factor such as transforminggrowthfactor-acts on fat-storing cell by activating, and increases collagen and generates, and finally causes liver fibrosis.This experimental result shows that rat is through CCl
4After stimulating for 6 weeks etc. complex factors, its hepatic tissue mda content significantly raises, and content of triglyceride significantly raises.MDA is the main degradation products of lipid peroxidation, but the structure of major injury cell membrane causes necrosis of liver cells.Medicine of the present invention can obviously reduce chronic liver injury liver tissues of rats mda content and content of triglyceride, improves the hepatic tissue activity, reduces the removing that oxygen radical generated and accelerated free radical, thereby alleviates oxygen radical to hepatocellular damage.This lipoid peroxidization resistant of health preserving liver protection tea of the present invention can play the effect of anti-chronic liver injury, and the result of treatment for hepatic injury also is significant simultaneously.
Experimental example 3
Have the effect that strengthens immunity by following zoopery proof medicine of the present invention, carry out zoopery according to Ministry of Public Health's " health food check and technical specification " (2003 editions) regulation.
1, sample:
It is grams every days 12 that medicine of the present invention becomes the human oral RD, and the adult calculates by body weight 60kg, takes out content and experimentizes.
2, animal used as test and grouping:
The healthy cleaning level of 18～22g Kunming kind of the Department Of Medicine, Peking University department of the Chinese Academy of Sciences of animal used as test section [credit number: SCXK-(capital) 2002-0001] breeding male mice, totally 120.Every group 40, divide 3 groups, immune 1 group is carried out carbon and cleans up experiment; The immunity 2 groups carry out dirty body ratio measurement, Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell test, tardy parasexuality reaction experiment, HD50 value (HC
50) must measure the mensuration with the antibody-producting cell number; Immunity is carried out mouse lymphocyte transformation experiment, the detection of NK cell activity that ConA induces for 3 groups.
3, dosage is selected:
5 times, 10 times, 30 times of the medicine adult recommended oral dose according to the present invention (gram every days 12) are divided into high, medium and low dosage group, water is mixed with desired concn, control group gives equal-volume distilled water, give animal subject respectively and irritate stomach, irritate stomach every day 1 time, irritate the long-pending 0.2ml/10gBW of being of body of stomach, continuous 45 days.
4, experimental technique:
(1) internal organs/weight ratio pH-value determination pH: mouse is put to death in the back of weighing, and takes out spleen and thymus gland, weighs on electronic analytical balance, calculates dirty/body ratio.
(2) delayed allergy (DTH) (the sufficient sole of the foot thickens method)
After mouse peritoneal injection 2% (v/v) SRBC (the every mouse of 0.2ml/) sensitization 4 days, measure left back sufficient sole of the foot thickness, and then measuring point hypodermic injection 2% (v/v) SRBC (the every mouse of 20 μ l/), left back sufficient sole of the foot thickness measured in back 24 hours in injection, same position is measured three times, averages.Metapedes sole of the foot thickness difference (swelling degree of the paw) was represented the DTH degree in the past.
(3) the ConA mouse lymphocyte transformation experiment of inducing
The aseptic spleen of getting places the little plate that fills an amount of aseptic Hank ' s liquid, makes cell suspension, filters through 200 eye mesh screens.Use Hank ' s liquid to wash 3 times, each centrifugal 10 minutes (1000rpm).Then cell is suspended in the 2ml complete medium, the living cell counting number, adjusting cell concentration with the RPMI640 nutrient solution is 5 * 10
6Individual/ml, again cell suspension is divided two holes to add in the 24 hole plates, every hole 1ml, a hole adds 50 μ l ConA liquid (being equivalent to 5 μ g/ml) therein, and 5% carbon dioxide is put in contrast in another hole, cultivates 72 hours for 37 ℃.Cultivate and finish preceding 4 hours, supernatant 0.7ml is inhaled in every hole gently, adds the RPMI640 nutrient solution that does not contain calf serum, add MTT (5mg/ml) 50 μ l/ holes simultaneously, after continuing to finish, every hole adds 1ml acid isopropyl alcohol, the piping and druming mixing dissolves purple crystal fully.Then this liquid is measured wavelength 570nm with ELIASA.Lymphocytic multiplication capacity deducts the OD value that does not add the ConA hole with the OD value that adds the ConA hole and represents.
(4) antibody-producting cell detects (Jeme improvement wave plate method)
Get sheep blood, with physiological saline washing 3 times, each centrifugal 10 minutes (200r/min) will overstock SRBC and be made into the cell suspension of 2% (v/v), every mouse lumbar injection 0.2mL with physiological saline.Mouse that immunity is back 4 days is put to death, and gets spleen, tears up gently, makes cell suspension with Hanks liquid, and 200 orders sieve, and washs, centrifugal 2 times, cell is suspended in the 5mL Hanks liquid at last.Top layer culture medium heating fusion back is mixed with the pH7.4 of equivalent, the Hanks liquid of 2 times of concentration, the packing small test tube, every pipe 0.5mL, in pipe, add 10%SRBC 50 μ l (v/v)/20 μ l splenocyte suspensions again with the preparation of SA liquid, be poured on the wave plate of brushing the thin layer agarose behind the mixing rapidly, treat after agarose solidifies wave plate level button to be placed on the wave plate frame, putting into the CO2gas incubator temperature bathed 1.5 hours, complement (1: 10) with the dilution of SA liquid joins in the wave plate groove then, continues temperature and bathes counting hemolysis plaque number after 1.5 hours.
(5) HD50 value (HC
50) mensuration
Get sheep blood, with physiological saline washing 3 times, every mouse lumbar injection 2% (v/v prepares with physiological saline) hematocrit SRBC 0.2mL carries out immunity, after 5 days, extract eyeball and get blood in centrifuge tube, placed about 1 hour, solidification blood and tube wall are peeled off, serum is fully separated out, centrifugal 10 minutes of 2000rpm collects serum.Is 200 times with the SA buffer solution with the serum dilution, gets 1mL in vitro, adds 10% (v/v is with the preparation of SA buffer solution) hematocrit SRBC 0.5mL successively, complement 1mL (pressing dilution in 1: 10 with the SA buffer solution).Other establishes the not control tube of increase serum (replacing with the SA buffer solution).Put in 37 ℃ of water-baths insulation after 30 minutes, the ice bath cessation reaction.Centrifugal 10 minutes of 2000rpm, get supernatant 1mL, add Dou Shi reagent 3mL, (v/v is with the preparation of SA buffer solution) the hematocrit SRBC 0.25mL that gets 10% simultaneously, add Dou Shi reagent to 4mL in another test tube, fully mix, place after 10 minutes, sentence control tube in 540nm and make blank, measure respectively and respectively manage OD value.The amount of hemolysin is with HD50 value (HC
50) expression, be calculated as follows: HD50 value (HC
50OD value * extension rate during)=sample OD value/SRBC HD50.
(6) mouse carbon is cleaned up experiment
Mouse tail vein injection is with the prepared Chinese ink of 4 times of physiological saline dilutions, every 10g body weight injection 0.1mL, and timing immediately after prepared Chinese ink injects and was injected behind the prepared Chinese ink 2,10 minutes, got blood 20 μ l with angular vein respectively, joined 2mLNa
2CO
3Shake up in the solution.With Na
2CO
3Solution is made blank, with 722 type spectrophotometers at 600nm wavelength place colorimetric photometry density value (OD).Mouse is put to death, get the liver spleen, weigh, calculate phagocytic index a.
(7) Turnover of Mouse Peritoneal Macrophages is engulfed the chicken red blood cell experiment
Mouse peritoneal injection 20% (v/v, prepare with physiological saline) hematocrit chicken red blood cell (2000rpm, 10min) suspension 1mL, 30 minutes at interval, the cervical vertebra dislocation is put to death, and gets peritoneal macrophage washing lotion 1mL, drips on wave carrier piece, put in the enamel box that is lined with wet gauze, put 37 ℃ of incubator incubations 30 minutes.Incubate completely, rinsing in physiological saline to remove the paster cell, is dried.With methyl alcohol: propyl alcohol (1: 1) is fixing, and the dyeing of 4% (v/v) Giemsa-phosphate buffer is dried with the distilled water rinsing again.The oil mirror is counting down, and 100 macrophages of every counting are calculated as follows phagocytic rate and phagocytic index:
Phagocytic rate %=engulfs macrophage number * 100% of the macrophage number/counting of chicken red blood cell
The macrophage number of chicken red blood cell sum/counting that phagocytic index=quilt is engulfed.
(8) the NK cytoactive is measured
Get go down to posterity back 24 hours well-grown YAC-1 cell (survival rate＞95%) by 1 * 10
6/ mLYAC-1 cell suspension adds
3H-TdR10 μ lCi carries out mark, cultivates 2 hours in 37 ℃ of 5% CO2gas incubator, shakes once in per 30 minutes, and the cell behind the mark is resuspended in the nutrient solution with nutrient solution washing 3 times, is that cell concentration is 1 * 10
5Individual/mL.Tried the dislocation of mouse cervical vertebra and put to death, the aseptic spleen of getting is made splenocyte suspension, with Hanks washing 3 times, each 1000rpm10 minute, contain the RPMI640 complete medium of 10% calf serum again with 2mL, with the blue dyeing counting of platform phenol (or cell number should more than 95%), adjusting cell concentration be 1 * 10
7Individual/mL.Every hole adds the target cell of 100 μ l marks in 96 orifice plates, and test hole adds 100 μ l effector cells, and blank group hole adds 100 μ l culture mediums, and maximum rare discharge hole adds 100 μ lTritonX-100.Each sample is established 3 multiple holes, puts 5% carbon dioxide, cultivates 4 hours for 37 ℃.Get storage with the bull cell and get and combine on the glass fiber filter paper, measure per minute umber of pulse (cpm) with liquid scintillation instrument
NK cytoactive=(1-experimental port cpm/ (the maximum release aperture cpm of blank hole cpm-)) * 100%
5, experimental data statistics: carry out statistical analysis with Excel/Spss software.
6, experimental result
Table 8 is respectively organized the initial body weight of mouse
| The dosage group | 1 group of immunity | 2 groups of immunity | 3 groups of immunity | |||
| Number of animals (only) | Body weight | Number of animals (only) | Body weight | Number of animals (only) | Body weight | |
| Control group | 10 | 18.9±1.0 | 10 | 18.7±1.0 | 10 | 18.8±0.8 |
| Low dose group | 10 | 18.6±0.9 | 10 | 18.6±1.0 | 10 | 18.8±1.0 |
| Middle dosage group | 10 | 18.8±1.0 | 10 | 18.8±0.9 | 10 | 18.8±0.9 |
| High dose group | 10 | 18.9±0.8 | 10 | 18.9±0.9 | 10 | 18.9±1.0 |
Table 9 is respectively organized mouse body weight in mid-term
| The dosage group | 1 group of immunity | 2 groups of immunity | 3 groups of immunity | |||
| Number of animals (only) | Body weight | Number of animals (only) | Body weight | Number of animals (only) | Body weight | |
| Control group | 10 | 28.5±1.2 | 10 | 28.7±1.5 | 10 | 28.8±1.4 |
| Low dose group | 10 | 28.8±1.9 | 10 | 28.6±1.6 | 10 | 28.9±1.5 |
| Middle dosage group | 10 | 28.7±1.6 | 10 | 28.8±1.5 | 10 | 28.7±1.6 |
| High dose group | 10 | 28.9±1.8 | 10 | 28.9±1.7 | 10 | 28.1±1.5 |
Table 10 is respectively organized mouse body weight tailend
| The dosage group | 1 group of immunity | 2 groups of immunity | 3 groups of immunity | |||
| Number of animals (only) | Body weight | Number of animals (only) | Body weight | Number of animals (only) | Body weight | |
| Control group | 10 | 38.7±1.6 | 10 | 38.5±1.5 | 10 | 38.6±1.8 |
| Low dose group | 10 | 38.6±1.9 | 10 | 38.8±1.2 | 10 | 38.5±1.6 |
| Middle dosage group | 10 | 38.8±1.5 | 10 | 38.7±1.9 | 10 | 38.7±1.7 |
| High dose group | 10 | 38.9±1.8 | 10 | 38.9±2.0 | 10 | 38.6±1.5 |
Table 11 is respectively organized weight of mice
| The dosage group | 1 group of immunity | 2 groups of immunity | 3 groups of immunity | |||
| Number of animals (only) | Body weight | Number of animals (only) | Body weight | Number of animals (only) | Body weight | |
| Control group | 10 | 19.8±1.3 | 10 | 19.8±1.3 | 10 | 19.8±1.3 |
| Low dose group | 10 | 20.0±1.2 | 10 | 20.2±1.2 | 10 | 19.7±1.3 |
| Middle dosage group | 10 | 20.0±1.4 | 10 | 19.9±1.4 | 10 | 19.9±1.3 |
| High dose group | 10 | 20.0±1.0 | 10 | 20.0±1.5 | 10 | 19.7±1.3 |
By table 8-11 as seen, the experiment of each dosage group just, in, latter stage the mouse body weight and the contrast of experimental session weight of mice compare there was no significant difference (P＞0.05).
Table 12 medicine of the present invention is to the influence of mouse immune organ internal organs/body weight ratio
| The dosage group | Number of animals (only) | Spleen/body weight | Thymus gland/body weight | ||
| (％) | The P value | (％) | The P value | ||
| Control group | 10 | 0.52±0.05 | - | 0.38±0.03 | - |
| Low dose group | 10 | 0.54±0.04 | 0.802 | 0.36±0.05 | 0.952 |
| Middle dosage group | 10 | 0.53±0.05 | 0.763 | 0.37±0.04 | 0.756 |
| High dose group | 10 | 0.54±0.04 | 0.961 | 0.36±0.03 | 0.954 |
By table 12 as seen, per os gives the medicine of the present invention 45 days of mouse various dose, to mouse spleen/body weight and thymus gland/body weight ratio do not make significant difference (P＞0.05).
Table 13 medicine of the present invention is to the influence of mouse delayed allergy (DTH) (x ± s)
| The dosage group | Number of animals (only) | Inject back 2 hours swelling degree of the paw (mm) | The P value |
| Control group | 10 | 0.387±0.069 | - |
| Low dose group | 10 | 0.496±0.124 | - |
| Middle dosage group | 10 | 0.543±0.164* | P＜0.05 |
| High dose group | 10 | 0.572±0.136* | P＜0.05 |
*: conspicuousness is relatively arranged with control group
As shown in Table 13, per os gives the medicine of the present invention 45 days of mouse various dose, and dosage group mouse swelling degree of the paw and control group relatively have the trend of increasing, middle and high dosage group and control group relatively, difference has conspicuousness (P＜0.05).
The influence that table 14 medicine of the present invention is tested the mouse lymphocyte multiplication capacity (x ± s)
| The dosage group | Number of animals (only) | Lymphopoiesis ability (OD difference) | The P value |
| Control group | 10 | 0.059±0.027 | - |
| Low dose group | 10 | 0.089±0.032 | - |
| Middle dosage group | 10 | 0.096±0.050 | - |
| High dose group | 10 | 0.145±0.046* | P＜0.05 |
As shown in Table 14, per os gives the medicine of the present invention 45 days of mouse various dose, and each dosage group has the trend of increasing to the mouse lymphocyte conversion capability, high dose group and control group relatively, difference has conspicuousness (P＜0.05).
Table 15 medicine of the present invention is to the influence of mouse antibodies cellulation number
| The dosage group | Number of animals (only) | Hemolysis plaque number (* 10 3/ full spleen) | The P value |
| Control group | 10 | 19.96±7.32 | - |
| Low dose group | 10 | 23.67±7.59 | - |
| Middle dosage group | 10 | 29.85±8.24* | P＜0.05 |
| High dose group | 10 | 32.32±8.53* | P＜0.05 |
*: conspicuousness is relatively arranged with control group
As shown in Table 15, per os gives the medicine of the present invention 45 days of mouse various dose, and each dosage group mouse antibodies generates number and control group relatively has the trend of increasing, and middle and high dosage group and control group comparing difference have conspicuousness (P＜0.05).
Table 16 medicine of the present invention is to mouse HD50 value (HC
50) influence
| The dosage group | Number of animals (only) | The HD50 value | The P value |
| Control group | 10 | 180.2±45.3 | - |
| Low dose group | 10 | 235.9±49.2 | - |
| Middle dosage group | 10 | 261.3±53.0* | P＜0.05 |
| High dose group | 10 | 272.6±58.4* | P＜0.01 |
*: conspicuousness is relatively arranged with control group
As shown in Table 16, per os gives the medicine of the present invention 45 days of mouse various dose, and each dosage group mouse HD50 value and control group relatively have the trend of increasing, in (P＜0.05), high dose group (P＜0.01) have conspicuousness with the control group comparing difference.
Table 17 medicine of the present invention is to influence that mouse monokaryon-macrophage carbon is cleaned up
| The dosage group | Number of animals (only) | Phagocytic index (a) | The P value |
| Control group | 10 | 5.39±1.30 | - |
| Low dose group | 10 | 6.10±1.01 | - |
| Middle dosage group | 10 | 7.21±1.32* | P＜0.01 |
| High dose group | 10 | 7.86±1.24* | P＜0.01 |
*: conspicuousness is relatively arranged with control group
As shown in Table 17, per os gives the medicine of the present invention 45 days of mouse various dose, and each dosage group mouse phagocytic index and control group relatively have the trend of increasing, and middle and high dosage group mouse phagocytic index and control group comparing difference have conspicuousness (P＜0.01).
Table 18 medicine of the present invention is engulfed the influence (x ± s) of chicken red blood cell phagocytic rate to mouse macrophage
| The dosage group | Number of animals (only) | Phagocytic rate (%) | Phagocytic rate square root arcsine conversion value | The P value |
| Control group | 10 | 28.4±6.4 | 32.0±4.0 | - |
| Low dose group | 10 | 29.5±6.2 | 33.1±3.9 | P＞0.05 |
| Middle dosage group | 10 | 30.9±5.3 | 33.9±2.9 | P＞0.05 |
| High dose group | 10 | 31.0±5.6 | 33.5±3.5 | P＞0.05 |
Table 19 medicine of the present invention is engulfed the influence (x ± s) of chicken red blood cell phagocytic index to mouse macrophage
| The dosage group | Number of animals (only) | Phagocytic index | The P value |
| Control group | 10 | 0.842±0.272 | - |
| Low dose group | 10 | 0.901±0.276 | P＞0.05 |
| Middle dosage group | 10 | 1.011±0.263 | P＞0.05 |
| High dose group | 10 | 0.986±0.252 | P＞0.05 |
By table 18,19 as can be known, per os gives the medicine of the present invention 45 days of mouse various dose, and each dosage group mouse macrophage is engulfed the chicken red blood cell ability and do not seen obvious influence (P＞0.05).
Table 20 medicine of the present invention is to the influence of NK cells in mice activity
| The dosage group | Number of animals (only) | NK cytoactive (%) | NK cytoactive square root arcsine conversion value | The P value |
| Control group | 10 | 35.8±6.0 | 37.2±3.5 | - |
| Low dose group | 10 | 37.9±5.9 | 40.3±3.8 | - |
| Middle dosage group | 10 | 39.8±6.2 | 46.9±3.6* | P＜0.05 |
| High dose group | 10 | 40.6±5.9 | 49.5±4.0* | P＜0.05 |
*: conspicuousness is relatively arranged with control group
As shown in Table 20, per os gives the medicine of the present invention 45 days of mouse various dose, and each dosage group NK cells in mice is active relatively to have the trend of increasing with control group, and middle and high dosage group and control group comparing difference have conspicuousness (P＜0.05).
7, experimental result explanation:
Per os gives the basic, normal, high dosage of mouse medicine of the present invention 45 days, and delayed allergy, HD50 value, antibody-producting cell number, the monokaryon-macrophage carbon that can improve mouse is cleaned up mouse lymphocyte conversion capability and the NK cell activity that ability, ConA are induced.To the ability that weight of mice, thymus gland body weight ratio, spleen body weight ratio, mouse macrophage are engulfed chicken red blood cell, all there is not obviously influence.Above experimental result illustrates that health preserving liver protection tea of the present invention has the effect that strengthens immunity.
Experimental example 4
Medicine of the present invention carries out the security toxicology test according to " health food check and assessment technique standard " (2003 editions), and evaluation result is as follows:
1, acute oral LD
50Result: to acute oral LD female, male mouse
50All, belong to non-poisonous material greater than 21500mg/kgBW.
2, three genetic toxicity test results: the result is all negative for three genetic toxicity tests (Salmonella reversion test, PCEMNR micronucleus test, mouse sperm deformity test).
3, fed the result in 30 days: with 5 times, 10 times, 30 times of adult's RD (adult's RD is grams every days 12) is that the medicine of the present invention of basic, normal, high dosage is given rat oral gavage 45 days, duration of test, each dosage group rat body weight growth, affairs utilization rate and control group relatively do not have significant difference (P＞0.05), and relatively there are no significant (P＞0.05) for female, male mouse blood biochemistry index, routine blood test index and liver/body, spleen/body, kidney/body, male mouse testis/body ratio and control group.Liver,spleen,kidney, stomach, duodenum, testis (ovary) tissue pathology checking do not have obvious damage.Medicine of the present invention nursing in 45 days rat is described, every index observing does not produce toxic and side effect.
Experimental example 5
Below be clinical drug human experiment experiment of the present invention, illustrate that medicine of the present invention has blood fat reducing function.
1, the diagnostic criteria of high fat of blood:
(1) serum total cholesterol TG＞6.5 mMs/liter;
(2) triglyceride TG＞2.2 mMs/liter;
(3) LDL-C LDL-C＞4.16 mMs/liter;
(4) highdensity lipoprotein-cholesterol HDL-C＜0.91 mM/liter;
2, the experimenter includes standard in
The crowd of simple dyslipidemia, keep usual diet, blood sampling is 2 times in half a year, if twice serum total cholesterol is 〉=5.5mmol/L or triglyceride 〉=1.8mmol/L person, wherein under-18s, over-65s, gestation or women breast-feeding their children, be associated with serious primary disease such as conscience kidney and hemopoietic system, mental patient, take in the relevant article influence of pharmic function of the present invention except the judgement person as a result in a short time.
3, experimenter's grouping:
Meet the high experimenter of 100 routine blood fat that the experimenter includes standard in, be divided into medicine group of the present invention and blank group at random:
Medicine group of the present invention: the male sex's 18 examples, women's 32 examples, minimum 35 years old of age, maximum 64 years old, average 49.50 ± 7.41 years old, average course of disease 3.21 ± 2.79 years.
Blank group: the male sex's 20 examples, women's 30 examples, minimum 36 years old of age, maximum 65 years old, average 50.50 ± 9.28 years old, average course of disease 3.50 ± 2.60 years.
4, instructions of taking: medicine group of the present invention is taken medicinal tea of the present invention, 6 grams/time, oral 3 times of every day, boiling water brews to be drunk, continuous 45 days.The blank group is taken placebo, and consumption is identical with medicine group of the present invention with number of times.
5, effective evaluation standard:
Effectively: serum total cholesterol (TC) reduces＞10%, and triglyceride (TG) reduces＞15%, HDL-C (HDL-C) rising＞0.104mmol/L.
Invalid: as not reach effective standard person.
6, the human feeding trial result judges
Table 21 cardinal symptom is improved situation
| Cardinal symptom | The example number | Effectively | Invalid | Total effective rate (%) |
| Sense of fatigue dizzy constipation uncomfortable in chest | 50(50) 50(50) 50(50) 50(50) | 40(2) 38(2) 42(6) 39(2) | 10(48) 12(48) 8(44) 11(48) | 80.00(4.00) 76.00(4.00) 84.00(12.00) 78.00(4.00) |
() is the blank group
Table 22 effect is judged
| The example number | Effectively | Invalid | Total effective rate | |
| Medicine group control group of the present invention | 50 50 | 42 3 | 8 47 | 84.00％* 6.00％ |
Compare * P＜0.05 between group
In a word, in 45 days, in 50 examples of medicine group of the present invention, the cholesterol 0.98 ± 0.89mmol/L that on average descends, the triglyceride 0.45 ± 0.59mmol/L that on average descends, wherein effective 42 examples, total effective rate 84.00%; In blank group 50 examples, the cholesterol 0.08 ± 0.43mmol/L that on average descends, the triglyceride 0.06 ± 0.31mmol/L that on average descends, wherein effective 3 examples, total effective rate 6.00%.Illustrate that medicine of the present invention has the effect of reducing blood lipid.
Experimental example 6
Below be clinical drug human experiment experiment of the present invention, illustrate that medicine of the present invention has therapeutic efficiency to chemical damage.
1, liver function diagnostic criteria:
(1) γ glutamyl transpeptidase (GGT): 5～50IU
(2) glutamic-pyruvic transaminase (ALT): 5～40IU
(3) glutamic-oxalacetic transaminease (AST): 5～40IU
2, the experimenter includes standard in
The crowd of simple dyslipidemia, keep usual diet, blood sampling is 2 times in half a year, if twice blood sampling liver function index failure, wherein under-18s, over-65s, gestation or women breast-feeding their children, be associated with serious primary diseases such as conscience kidney and hemopoietic system, mental patient, take the article influence relevant to except the judgement person as a result in a short time with pharmic function of the present invention.
3, experimenter's grouping:
Meet the 100 routine experimenters that the experimenter includes standard in, be divided into drug study group of the present invention and control group at random:
Test-meal group: the male sex's 30 examples, women's 20 examples, minimum 33 years old of age, maximum 62 years old, average 47.50 ± 6.78 years old, average course of disease 6.21 ± 2.18 years.
Blank group: the male sex's 32 examples, women's 18 examples, minimum 32 years old of age, maximum 61 years old, average 46.50 ± 7.16 years old, average course of disease 6.50 ± 2.03 years.
4, instructions of taking: medicine test-meal group of the present invention is taken medicine medicinal tea of the present invention, 6 grams/time, oral 3 times of every day, boiling water brews to be drunk, continuous 45 days.Control group is taken the import fenofibrate, and consumption is identical with experimental group with number of times.
5, effective evaluation standard:
Effectively: every index near or reach normal value.
Invalid: as not reach effective standard person.
6, the human feeding trial result judges
Table 23 is taken the variation of transaminase content in the blood of medicine of the present invention front and back
| Group | The example number | AST(IU) | ALT(IU) | γ glutamyl transpeptidase (γ-GT) (IU) | |||
| Before | After | Before | After | Before | After | ||
| The test-meal group | 50 | 45.6 | 31.1 | 49.3 | 28.6 | 67.6±6.5 | 38.2±3.5 |
| Control group | 50 | 46.2 | 42.5 | 48.6 | 40.6 | 69.2±5.6 | 52.3±4.3 |
Table 23 shows, it is basic identical to treat preceding two groups hepatocellular damage degree, the test-meal group of taking medicine of the present invention, and liver function is clearly better, and it is undesirable to take the control group liver function recovery of import fenofibrate.
Table 24 effect is judged
| The example number | Effectively | Invalid | Total effective rate | |
| Test-meal group control group | 50 50 | 48 29 | 2 21 | 96.00％* 58.00％ |
Compare * P＜0.05 between group
In a word, in 45 days, in 50 examples of medicine test-meal group of the present invention, wherein effective 48 examples, total effective rate 96.00%; In control group 50 examples, wherein effective 29 examples, total effective rate 58.00%.Illustrate that medicine of the present invention has better curative effect to liver function recovery.
Advantage of the present invention and beneficial effect: medicinal herb tea of the present invention contains rich nutrient contents, wherein contains multiple saponin, organic acid, Glucosamine and polysaccharide.Through zoopery and clinical trial certificate, have the effect of treatment, conditioning and prevention chemical damage, for improving the body immunity aspect remarkable result is arranged, simultaneously fatty liver is had the supplemental treatment effect, without any side effects.
Medicine of the present invention is drunk as medicinal tea, its take with easy to carry, mouthfeel good.
The specific embodiment
Further set forth medicine of the present invention and preparation method thereof by following examples,,, all can reach described effect by the clinical trial checking by the health preserving liver protection medicinal herb tea of the present invention of following proportioning preparation.
Embodiment 1 medicine medicinal tea preparation of the present invention
(1) take by weighing gynostemma pentaphylla 25g, hawthorn 12g, fruit of Chinese wolfberry 11g, red sage root 8g, fleece-flower root 8g, glossy ganoderma 7g, root of kudzu vine 5g, dried orange peel 5g, dandelion 2g, standby;
(2) with hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, the dandelion boiling of described weight proportion three times, add for the first time 10 times of amounts of water and soak after 190 minutes, decocts 180 minutes, add for the second time 6 times of amounts of water decoct 120 minutes, add 2 times of amount decoctions of water 65 minutes for the third time.Extract is concentrated to and records relative density when 60 spend is 1.09～1.20 concentrate;
(3) gynostemma pentaphyllum powder of described weight proportion is broken to the meal of 50 order fineness;
(4) with concentrate when keeping 36 degree temperature and the gynostemma pentaphylla meal mix, fry and mix 75 minutes;
(5) pack, 4 KGY of cobalt-60 irradiation 180 minutes, promptly make medicinal tea.
Embodiment 2
(1) take by weighing gynostemma pentaphylla 20g, hawthorn 16g, fruit of Chinese wolfberry 16g, red sage root 10g, fleece-flower root 10g, glossy ganoderma 15g, root of kudzu vine 12g, dried orange peel 9g, dandelion 8g, standby;
(2) with hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, the dandelion boiling of described weight proportion three times, add for the first time 10 times of amounts of water and soak after 190 minutes, decocts 180 minutes, add for the second time 6 times of amounts of water decoct 120 minutes, add 2 times of amount decoctions of water 65 minutes for the third time.Extract is concentrated to by the concentrate that records relative density 1.09～1.20 when 60 spend;
(3) gynostemma pentaphyllum powder of described weight proportion is broken to the meal of 50 order fineness;
(4) with concentrate when keeping 36 degree temperature and the gynostemma pentaphylla meal mix, fry and mix 85 minutes;
(5) pack back is under 70 ℃ temperature dry 9 hours, promptly makes medicinal tea.
Embodiment 3
(1) take by weighing gynostemma pentaphylla 20g, hawthorn 9g, fruit of Chinese wolfberry 15g, red sage root 6g, fleece-flower root 6g, glossy ganoderma 10g, root of kudzu vine 8g, dried orange peel 5g, dandelion 3g, standby;
(2) except that gynostemma pentaphylla be that 50% alcohol immersion is put into the reflux alcohol reflux and extracted three times after 24 hours, for the first time with 8 times of amount alcohol refluxs 2 hours, measure alcohol refluxs 1.5 hours, measured alcohol refluxs 1 hour with 4 times for the third time with 6 times for the second time with each bulk drug volume ratio;
(3) reclaim extract also by 120 order stainless steel sift net filtrations;
(4) extract after will sieving 45 ℃ dry down, obtain dry extract;
(5) gynostemma pentaphylla with dry extract and described weight proportion mixes, and promptly makes active component;
(6) with the dry pack of above-mentioned active component, promptly made the medicinal tea finished product.
The granule preparation of embodiment 4 medicines of the present invention
(1) take by weighing gynostemma pentaphylla 15g, hawthorn 16g, fruit of Chinese wolfberry 12g, red sage root 10g, fleece-flower root 10g, glossy ganoderma 15g, root of kudzu vine 10g, dried orange peel 3g, dandelion 8g, standby;
(2) with hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, the dandelion boiling of described weight proportion three times, add for the first time 10 times of amounts of water and soak after 190 minutes, decocts 180 minutes, add for the second time 6 times of amounts of water decoct 120 minutes, add 2 times of amount decoctions of water 65 minutes for the third time.Extract is concentrated to when 60 spend, and records relative density and be 1.09～1.20 concentrate;
(3) gynostemma pentaphyllum powder of described weight proportion is broken to the meal of 50 order fineness;
(4) with concentrate when keeping 36 degree temperature and the gynostemma pentaphylla meal mix, fry and mix 90 minutes, promptly make active component;
(5) active constituent is added ethanol and make adhesive, add starch and do filler, be pressed into granule.
The preparation of embodiment 5 bolus of drug of the present invention
Main active component in this prescription is made ball shape preparation, be divided into common (large and small) ball shape preparation and little dropping pill formulation.The adhesive difference of using can be made into honeyed bolus, the water-bindered pill, starched pill, wax-wrapped pill and condensed pill etc.
(1) take by weighing gynostemma pentaphylla 20g, hawthorn 12g, fruit of Chinese wolfberry 15g, red sage root 8g, fleece-flower root 6g, glossy ganoderma 10g, root of kudzu vine 8g, dried orange peel 5g, dandelion 5g, standby;
(2) with hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, the dandelion boiling of described weight proportion three times, add for the first time 10 times of amounts of water and soak after 190 minutes, decocts 180 minutes, add for the second time 6 times of amounts of water decoct 120 minutes, add 2 times of amount decoctions of water 65 minutes for the third time.Extract is concentrated to when 60 spend, and records relative density and be 1.09～1.20 concentrate;
(3) gynostemma pentaphyllum powder of described weight proportion is broken to the meal of 120 order fineness;
(4) concentrate and gynostemma pentaphylla meal are mixed, fry and mix 95 minutes, promptly make active component;
(5) active constituent is added suitable adhesive and auxiliary material and make spherical preparation.
Claims (6)
1, a kind of health preserving liver protection tea is characterized in that, it is to be made by the following weight proportion raw material:
Gynostemma pentaphylla 15～25 weight portion hawthorn 9～16 weight portion fruits of Chinese wolfberry 11～16 weight portions
The red sage root 6～10 weight portion fleece-flowers root 6～10 weight portion glossy ganodermas 7～15 weight portions
The root of kudzu vine 5～12 weight portion dried orange peels 3～9 weight portion dandelions 2～8 weight portions
2, a kind of health preserving liver protection tea according to claim 1 is characterized in that, the weight proportion of each raw material is:
Gynostemma pentaphylla 15～20 weight portion hawthorn 12～16 weight portion fruits of Chinese wolfberry 12～16 weight portions
The red sage root 8～10 weight portion fleece-flowers root 8～10 weight portion glossy ganodermas 10～15 weight portions
The root of kudzu vine 8～10 weight portion dried orange peels 5～9 weight portion dandelions 5～8 weight portions
3, according to the preparation method of claim 1 or 2 described a kind of health preserving liver protection teas, it is characterized in that it comprises the following steps:
(1) take by weighing gynostemma pentaphylla, hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, dandelion by described weight proportion, standby;
(2) with hawthorn, the fruit of Chinese wolfberry, the red sage root, the fleece-flower root, glossy ganoderma, the root of kudzu vine, dried orange peel, the dandelion boiling of described weight proportion, extract is concentrated to and records relative density when 60 spend is 1.09～1.2 concentrate;
(3) gynostemma pentaphyllum powder of described weight proportion is broken to the meal of 50 order fineness;
(4) with concentrate when keeping 36 degree temperature and the gynostemma pentaphylla meal mix, fry and mix 75～95 minutes, promptly be prepared into active component of the present invention.
4, the preparation method of a kind of health preserving liver protection tea according to claim 3, it is characterized in that, boiling is three times in the described step (2), add for the first time 10 times of amounts of water and soak after 190 minutes, decocts 180 minutes, add for the second time 6 times of amounts of water decoct 120 minutes, add 2 times of amount decoctions of water 65 minutes for the third time.
5, the preparation method of a kind of health preserving liver protection tea according to claim 3 is characterized in that, the active component pack back that step (4) is made under 70 ℃～80 ℃ temperature dry 9～12 hours promptly makes medicinal tea.
6, the preparation method of a kind of health preserving liver protection tea according to claim 3 is characterized in that, 4 KGY are shone with cobalt-60 in the active component pack back that step (4) makes, and 180 minutes, promptly makes medicinal tea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610066319XA CN100544605C (en) | 2006-03-28 | 2006-03-28 | Health preserving liver protection tea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610066319XA CN100544605C (en) | 2006-03-28 | 2006-03-28 | Health preserving liver protection tea and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1820618A true CN1820618A (en) | 2006-08-23 |
| CN100544605C CN100544605C (en) | 2009-09-30 |
Family
ID=36922315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610066319XA Active CN100544605C (en) | 2006-03-28 | 2006-03-28 | Health preserving liver protection tea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100544605C (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664087B (en) * | 2009-08-31 | 2011-05-11 | 通化腾龙生物科技有限公司 | Health-care liver benefiting tea |
| CN102265950A (en) * | 2011-01-12 | 2011-12-07 | 余海生 | Mind-calming, eye-brightening, restlessness-removing and fatigue-resisting tea for drivers and preparation method thereof |
| CN102342351A (en) * | 2011-09-07 | 2012-02-08 | 温州市天禾生物科技有限公司 | Liver-protection tea |
| CN101803730B (en) * | 2009-11-12 | 2012-08-22 | 天津市百奥生物技术有限公司 | Health care food with auxiliary protection role on chemical liver injury and preparation method thereof |
| CN102669667A (en) * | 2012-05-25 | 2012-09-19 | 北京三奇本草医药技术有限公司 | Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof |
| CN102688303A (en) * | 2011-05-24 | 2012-09-26 | 郑彦 | Health liver-protecting tea and making method thereof |
| CN103125937A (en) * | 2013-02-04 | 2013-06-05 | 南京观海生医药科技有限公司 | De-alcoholic liver protection agent and preparation method thereof |
| CN103652192A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Liver protection tea |
| CN103689175A (en) * | 2013-12-27 | 2014-04-02 | 陈洁 | Liver and health protection tea |
| CN104782833A (en) * | 2015-03-24 | 2015-07-22 | 张建迎 | All-season health tea and preparation method thereof |
| CN105106483A (en) * | 2015-09-23 | 2015-12-02 | 董春年 | Traditional Chinese medicine electuary for treating fatty liver and preparation method thereof |
| CN105166227A (en) * | 2015-09-11 | 2015-12-23 | 李桂武 | Fat removal health-care tea |
| CN107551208A (en) * | 2017-07-31 | 2018-01-09 | 洛阳市乐享添年生物技术开发有限责任公司 | A kind of Chinese medicine and preparation method thereof of logical Liver Channel, detoxifying and descending turbid |
| CN109077165A (en) * | 2018-09-21 | 2018-12-25 | 林妙华 | A kind of herbal tea and preparation method thereof with benefiting qi and nourishing blood effect |
| CN113826737A (en) * | 2021-08-31 | 2021-12-24 | 成都营养屋健康科技有限公司 | Immune liver-protecting tea and preparation method thereof |
-
2006
- 2006-03-28 CN CNB200610066319XA patent/CN100544605C/en active Active
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664087B (en) * | 2009-08-31 | 2011-05-11 | 通化腾龙生物科技有限公司 | Health-care liver benefiting tea |
| CN101803730B (en) * | 2009-11-12 | 2012-08-22 | 天津市百奥生物技术有限公司 | Health care food with auxiliary protection role on chemical liver injury and preparation method thereof |
| CN102265950A (en) * | 2011-01-12 | 2011-12-07 | 余海生 | Mind-calming, eye-brightening, restlessness-removing and fatigue-resisting tea for drivers and preparation method thereof |
| CN102265950B (en) * | 2011-01-12 | 2012-11-21 | 余海生 | Mind-calming, eye-brightening, restlessness-removing and fatigue-resisting tea for drivers and preparation method thereof |
| CN102688303B (en) * | 2011-05-24 | 2014-03-26 | 郑彦 | Health liver-protecting tea and making method thereof |
| CN102688303A (en) * | 2011-05-24 | 2012-09-26 | 郑彦 | Health liver-protecting tea and making method thereof |
| CN102342351A (en) * | 2011-09-07 | 2012-02-08 | 温州市天禾生物科技有限公司 | Liver-protection tea |
| CN102669667B (en) * | 2012-05-25 | 2013-07-17 | 北京三奇本草医药技术有限公司 | Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof |
| CN102669667A (en) * | 2012-05-25 | 2012-09-19 | 北京三奇本草医药技术有限公司 | Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof |
| CN103125937A (en) * | 2013-02-04 | 2013-06-05 | 南京观海生医药科技有限公司 | De-alcoholic liver protection agent and preparation method thereof |
| CN103652192A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Liver protection tea |
| CN103689175A (en) * | 2013-12-27 | 2014-04-02 | 陈洁 | Liver and health protection tea |
| CN104782833A (en) * | 2015-03-24 | 2015-07-22 | 张建迎 | All-season health tea and preparation method thereof |
| CN105166227A (en) * | 2015-09-11 | 2015-12-23 | 李桂武 | Fat removal health-care tea |
| CN105106483A (en) * | 2015-09-23 | 2015-12-02 | 董春年 | Traditional Chinese medicine electuary for treating fatty liver and preparation method thereof |
| CN107551208A (en) * | 2017-07-31 | 2018-01-09 | 洛阳市乐享添年生物技术开发有限责任公司 | A kind of Chinese medicine and preparation method thereof of logical Liver Channel, detoxifying and descending turbid |
| CN109077165A (en) * | 2018-09-21 | 2018-12-25 | 林妙华 | A kind of herbal tea and preparation method thereof with benefiting qi and nourishing blood effect |
| CN113826737A (en) * | 2021-08-31 | 2021-12-24 | 成都营养屋健康科技有限公司 | Immune liver-protecting tea and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100544605C (en) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1820618A (en) | Health preserving liver protection tea and its preparing method | |
| CN102100805B (en) | Composition for relieving physical fatigue and enhancing immunologic function, preparation method thereof and application thereof | |
| CN104041903B (en) | A kind of rich selenium blue or green money willow drink and preparation method thereof | |
| CN102907604B (en) | Health-care product having effects of reducing blood sugar and pressure, losing weight, relaxing bowels, maintaining beauty and resisting fatigue and production process thereof | |
| CN102940733B (en) | Composition for relieving physical fatigue and preparation method and application thereof | |
| CN104719535A (en) | Maca black tea composition capable of improving sub-health status of women and preparation method of maca black tea composition | |
| CN102242070A (en) | Method for artificially culturing paecilomyces cicadae and application of culturing product thereof | |
| CN1824763A (en) | Fire internal organ nourishing wine and its preparation technology | |
| CN103099089A (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN106072578A (en) | There is the enhancing enzyme composition of immune function of human body, effervescent tablet and preparation method | |
| CN106244371B (en) | A kind of hypoglycemic rhizoma polygonati grape health care wine and its production technology | |
| CN105532998A (en) | Health-care tea containing cordyceps militaris and preparation method thereof | |
| CN101142975A (en) | Rhodiola root and honey composition and preparation method thereof | |
| CN106107397A (en) | A kind of Andrias davidianus Blanchard protein peptide powder solid beverage formula and preparation method thereof | |
| CN103585400B (en) | Have and strengthen immunologic function and the compositions alleviating fatigue effect and preparation method thereof | |
| CN102422957B (en) | Bawei danshen tea and preparation process thereof | |
| CN104336174A (en) | Rhodiola rosea and milk vinegar contained green tea health beverage | |
| CN114042126B (en) | Traditional Chinese medicine composition for ascending clear, eliminating turbid, promoting diuresis, benefiting qi, losing weight and reducing fat and preparation method thereof | |
| CN102021101B (en) | Preparation method of healthy wine for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1736230B (en) | Fat-lowering weight-decreasing tea and preparation process thereof | |
| CN106075084A (en) | A kind of Herba Dendrobii beauty treatment medicated wine of stomach invigorating strengthening the spleen blood fat reducing and preparation method thereof | |
| CN106173092A (en) | Improve sleep quality kidney tonifying Hepatoprotective health tea and preparation method thereof | |
| CN101036722A (en) | Health-caring food for easing and improving climacteric Syndrome of men and the preparation thereof | |
| CN1232267C (en) | Compound plant medicine and its application | |
| CN109486613A (en) | One kind is for health liquor and its beverage and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Sanqi Medical Technology Co., Ltd. Assignor: Wang Xiao Contract record no.: 2011990000816 Denomination of invention: Health-preserving liver-protecting tea and preparation method thereof Granted publication date: 20090930 License type: Exclusive License Open date: 20060823 Record date: 20110824 |